Effective July 9, NIH-funded institutions that do not report relevant cases of misconduct—including sexual harassment, bullying, and retaliation—within one month would be considered to be in violation of NIH regulations and of federal law.
Karen E. Knudsen has spent the past year bringing the American Cancer Society into the 21st century.
Some things are known to grow well in Kansas. Some things aren’t. Over the past 18 years, Roy Jensen has been told time and again that it made no sense to even try to grow an NCI-designated Comprehensive Cancer Center in Kansas. Yet, he did the only thing he could. Persist. Stubbornly. The University of... […]
As conservative legislatures take the cue from the Supreme Court’s overturn of Roe v. Wade by enacting abortion restrictions, oncologists in many states are scrambling to figure out how to best care for their pregnant patients, said Alice Mims, a hematologist-oncologist at the Ohio State University Comprehensive Cancer Center – James.
Now that the constitutional right to abortion has been eliminated, U.S. healthcare providers have to choose one of three options: give up abortion services, relocate, or wrangle with enforcement and unfriendly state legislatures.
As she was interviewing for the director’s job at the George Washington Cancer Center, Julie E. Bauman was asked what her biggest fear would be.
Cancer organizations and pharmaceutical companies have formed a coalition that seeks to develop licensing agreements to improve access to essential cancer drugs in low- and lower-middle income countries (LLMICs).
When Judy Orem learned of her chronic myeloid leukemia diagnosis in 1995, she chose interferon over a treatment that seemed more risky—a bone marrow transplant.
Fox Chase Cancer Center used to be a place where Nobel laureates toiled. Now, people who love the place—and in oncology, many people do—are hoping that Jonathan Chernoff, Fox Chase’s new director, will restore vitality to the venerable Philadelphia-based cancer center.
FDA is asking sponsors of all investigational medical products to focus on including diverse patients throughout the clinical development process.
